ICAAC 2012: People with Low-level Viral Load Are at Risk for Treatment Failure and Poor CD4 Recovery
- Details
- Category: HIV Treatment
- Published on Wednesday, 26 September 2012 00:00
- Written by Liz Highleyman
Individuals who still have low levels of plasma HIV RNA despite taking antiretroviral therapy (ART) may experience treatment failure, and those with HIV residual DNA in their T-cells may not achieve expected CD4 cell gains, according to 2 studies presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco. 
DHHS Implements Common Application for HIV Patient Assistance Programs
- Details
- Category: HIV Treatment
- Published on Friday, 14 September 2012 00:00
- Written by Press Release
A common application that allows people with HIV to apply for financial assistance for drugs from multiple companies went into effect on September 12, 2012. Individuals should now be able to obtain a complete antiretroviral regimen with a single form.
AIDS 2012: More People Starting HIV Treatment, Lower Viral Load in NA-ACCORD Study
- Details
- Category: HIV Treatment
- Published on Tuesday, 04 September 2012 00:00
- Written by Liz Highleyman
More than 80% of HIV patients in the large North American ACCORD study are receiving combination antiretroviral therapy (ART), about 70% have suppressed viral load -- up from less than 50% in 2000 -- and the median age at the time of death rose by 6 years, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.
Coverage of 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Details
- Category: HIV Treatment
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy -- better known as ICAAC -- in San Francisco, September 9-12, 2012.
Topics highlighted this year include experimental antiretroviral drugs, complications related to HIV and its treatment, recent developments in hepatitis C therapy, and cancer caused by HPV, along with a gamut of other infectious diseases including influenza, tuberculosis, and STDs.
HIVandHepatitis.com ICAAC 2012 conference section
9/11/12
HIV Attachment Inhibitor BMS-663068 Looks Good in Early Studies
- Details
- Category: HIV Treatment
- Published on Tuesday, 04 September 2012 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's novel attachment inhibitor pro-drug BMS-663068, which binds to HIV's gp120 envelope protein, potently suppressed viral load and was generally well-tolerated in a week-long monotherapy study, according to a report in the August 14, 2012, advance online edition of the Journal of Infectious Diseases. A related study showed that the active form of the drug worked against virus resistant to other entry inhibitors. 
More Articles...
- AIDS 2012: Triple Infection with HBV Promotes HCV Clearance in People with HIV
- AIDS 2012: No Interactions Seen Between New TB Drug and Popular HIV Meds
- AIDS 2012: Adding Nitazoxanide Does Not Improve Interferon Cure Rate for HIV/HCV Coinfected Patients
- AIDS 2012: Incomplete CD4 T-Cell Response to ART Raises Mortality Risk
Web Design and Development by